Last reviewed · How we verify
Clobetasol Propionate 0.05% Lotion
At a glance
| Generic name | Clobetasol Propionate 0.05% Lotion |
|---|---|
| Also known as | Clobex |
| Sponsor | MC2 Therapeutics |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis (PHASE4)
- Intradermal LPS and Antibiotics (NA)
- Subject Preference for Scalp Psoriasis Treatment (PHASE3)
- Evaluation of the Vasoconstriction Properties of MC2-01 Cream (PHASE1)
- Pivotal Bioequivalence Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects (PHASE1)
- The Dose-response "Pilot" Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects (PHASE1)
- A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clobetasol Propionate 0.05% Lotion CI brief — competitive landscape report
- Clobetasol Propionate 0.05% Lotion updates RSS · CI watch RSS
- MC2 Therapeutics portfolio CI